ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.

ABSTRACT:

Background

Anillin (ANLN), an actin-binding protein required for cytokinesis, has recently been presented as part of a prognostic marker panel in breast cancer. The objective of the current study was to further explore the prognostic and functional value of ANLN as a single biomarker in breast cancer.

Methods

Immunohistochemical assessment of ANLN protein expression was performed in two well characterized breast cancer cohorts (n = 484) with long-term clinical follow-up data and the results were further validated at the mRNA level in a publicly available transcriptomics dataset. The functional relevance of ANLN was investigated in two breast cancer cell lines using RNA interference.

Results

High nuclear fraction of ANLN in breast tumor cells was significantly associat

SUBMITTER: Magnusson K 

PROVIDER: S-EPMC5116155 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature